UCB, a global biopharmaceutical company, revealed promising results from its GEMZ phase 3 study of fenfluramine for treating seizures associated with CDKL5 Deficiency Disorder...
UCB, a global biopharmaceutical company, is set to present 26 scientific abstracts at the International Epilepsy Congress in Lisbon, Portugal, from August 30 to...